Ovary
ID:AAAB4456
Cooperative Group
Principal Investigator: Dr. Thomas Herzog
Adult:
RANDOMIZED PHASE3 TRIAL OF MAINTENANCE CHEMO COMPARING 12MONTHLY CYCLES OF SINGLE AGENT PACLITAXEL OR CT-2103 VS NO TREATMENT UNTIL DOCUMENTED RELAPSE IN WOMEN W/ ADVANCED OVARIAN, PRIMARY PERITONEAL OR FALLOPIAN CANCER WHO ACHIEVE CLINICAL RESPONSE TO PR
This study will investigate the use of several chemotherapy drugs in women with advanced ovarian or primary peritoneal cancer who achieve a complete clinical response to primary treatment with platinum/taxane chemotherapy. Patients will be randomized to receive the 12 monthly treatments with chemotherapy drugs paclitaxel or XYOTAX¿ (CT2103) (IND#70177), or no treatment until documented relapse of their cancer.; Please click here to view more information in ClinicalTrials.gov.
For more information and to inquire about eligibility for this study, please contact the Cancer Center office at 212-305-8615.
Ovary, Corpus Uteri
ID:AAAD8429
Institutional
Principal Investigator: Dr. Jason Wright
Adult:
Feasibility of Carboplatin, Paclitaxel and Bevacizumab Neoadjuvant Therapy for Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer
This study is to determine the feasibility of administering neoadjuvant carboplatin, placitaxel, and bevacizumab without excessive dose modification or cycle delay in patients with epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer. Please click here to view more information in ClinicalTrials.gov.
For more information and to inquire about eligibility for this study, please contact the Cancer Center office at 212-305-8615.
Ovary
ID:AAAD3949
Cooperative Group
Principal Investigator: Dr. Thomas Herzog
Adult:
PHASE III RANDOMIZED CONTROLLED CLINICAL TRIAL OF CARBOPLATIN AND PACLITAXEL ALONE OR IN COMBINATION WITH BEVACIZUMAB FOLLOWED BY BEVACIZUMAB AND SECONDARY CYTOREDUCTIVE SURGERY IN PLATINUM-SENSITIVE, RECURRENT OVARIAN CANCER
This is a randomized Phase III study to compare the combination of carboplatin, paclitaxel and bevacizumab to the standard combination of carboplatin and paclitaxel alone. Those patients for whom their treating physicians consider appropriate for surgery will be randomized to either secondary cytoreduction or no surgery prior to a second randomization of chemotherapy. This study seeks to determine if surgical secondary cytoreduction in addition to adjuvant chemotherapy increases the duration of overall survival in subjects with recurrent platinum sensitive epithelial ovarian cancer or peritoneal primary cancer. Also, this study determines if the addition of bevacizumab to the second-line and maintenance phases of treatment increases the duration of overall survival relative to second-line paclitaxel and carboplatin alone in patients with recurrent platinum sensitive epithelial ovarian cancer, peritoneal primary or fallopian tube cancer. Another aspect of this study is to collect tissue and blood specimens from patients who consent to participate in the translational research study. These results will be used for research purposes only, and published after completion of this research study. Patients will be asked to complete a quality of life questionnaire to assess the effects throughout the treatment. Please click here to view more information in ClinicalTrials.gov.
For more information and to inquire about eligibility for this study, please contact the Cancer Center office at 212-305-8615.
Ovary
ID:AAAI1246
Institutional
Principal Investigator: Dr. Sharyn Lewin
Adult:
A Phase II Combined Modality Protocol of Debulking Surgery Followed by Intraperitoneal Chemotherapy for the Treatment of Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancers.
Current surgical and/or chemotherapy treatment of patients with peritoneal cancers such as recurrent ovarian, primary peritoneal cancer or fallopian tube cancers are unsatisfactory and have not been shown to significantly prolong survival. In this study we will investigate whether a combination of different types of treatment can demonstrably improve the overall survival in patients with recurrent ovarian, primary peritoneal and fallopian tube cancers especially for those who may not have received IPC in the firstline setting.The potential significance of this research is that cytoreductive surgery in combination with heated intraoperative chemoperfusion (HIPEC), when combined with a course of outpatient IPC, has not been previously performed in this patient population and may confer a survival advantage over IV therapy.The proposed treatment will require the patient to undergo: (1) exploratory laparotomy/debulking surgery with total omentectomy, mediport catheter placement and intraoperative hyperthermic (warmed) chemotherapy, (2) 4 cycles (12 weeks) of outpatient intracavitary (intraperitoneal (IP)/abdominal) chemotherapy, and (3) a second surgical exploration with excision of residual disease followed by HIPEC and removal of catheters. In this way, we will be able to specifically target the cancer cells with directed intracavitary chemotherapy. We envision that this treatment will prolong the length of time patients remain disease-free post surgery in addition to the possibility that the length of survival may be prolonged. All patients will be followed for a maximum of 5 years from the time of study entry. It is hoped that this new regimen of combined surgery and localized chemotherapy is feasible, tolerable and safe and that its use will demonstrate an improved progression-free and overall survival. Please click here to view more information in ClinicalTrials.gov.
For more information and to inquire about eligibility for this study, please contact the Cancer Center office at 212-305-8615.
Ovary
ID:AAAF2672
Institutional
Principal Investigator: Dr. Jason Wright
Adult:
Phase II Trial of Combination Pemetrexed(Alimta) and Carboplatin (Paraplatin)in Platinum Sensitive Recurrent Ovarian, Primary Peritoneal,
and Fallopian Tube Carcinoma
Based on preclinical data, Pemetrexed is a promising agent for targeted ovarian cancer treatment. Furthermore, Carboplatin is an agent active in ovarian cancer treatment and has demonstrated antitumor activity when combined with Pemetrexed in other solid tumors. Normally, one of the standard treatments for ovarian, primary peritoneal or fallopian tube cancer at this point would be to administer Carboplatin alone. The study team would like to find out if adding Pemetrexed to Carboplatin in the treatment of recurrent ovarian cancer is helpful in improving tumor?s response to therapy than Carboplatin would be alone. The study team is also interested in finding out the type of side effects that can occur with this combination of drugs. The chemotherapy regimen consists of a dose of Pemetrexed followed by a dose of Carboplatin every 21 days. This is the length of one ?cycle?. Pemetrexed will be given to patients through a vein (intravenously) over approximately 10 minutes. After the Premetrexed is given, Carboplatin will be given to patients intravenously over 30-60 minutes. The amount of Carboplatin that patients receive will be based on their kidney function, age, and weight. Kidney function will be measured by a blood test before the beginning of each chemotherapy cycle. The Carboplatin dose may change from cycle to cycle if kidney function changes. Please click here to view more information in ClinicalTrials.gov.
For more information and to inquire about eligibility for this study, please contact the Cancer Center office at 212-305-8615.
Other Female Genital, Ovary
ID:AAAK5750
Industry
Principal Investigator: Dr. Thomas Herzog
Adult:
A Phase 3 Randomized, Double- Blind, Placebo- Controlled, Multi-Center Study of Amg 386 With Paclitaxel and Carboplatin as First line treatment of SUbjects With FIGO Stage III-iv Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers
Please click here to view more information in ClinicalTrials.gov.
For more information and to inquire about eligibility for this study, please contact the Cancer Center office at 212-305-8615.
| 
